文章詳目資料

Annals of Nuclear Medicine and Molecular Imaging

  • 加入收藏
  • 下載文章
篇名 Biodistribution of Tc-99m(I)- Tricarbonyl Labeled Trastuzumab as an Imaging Agent for Breast Cancer with HER2 Overexpression in an Animal Model
卷期 24:3
並列篇名 鎔99m(I)-三線基標誌trasωzumab單株抗體作為HER2過度表現乳癌造影劑之動物模式生物分佈
作者 Chao-LiangYenWan-Jou ChenSu-Tang LoKuo-Ting ChenChao-LingYaoTe-Wei LeeJem-Mau Lo
頁次 119-122
關鍵字 BiodistributionBreast cancerHerceptinHER-2Tc-99mTrastuzumabHerceptinHER2trastuzumab搭99m乳癌生物分佈
出刊日期 201109

中文摘要

方法:將一組BALB/c-nu小鼠植入BT-474乳癌腫瘤(其HER2高度表現),男外將一組BALB/c-nu小鼠植入MCF-7乳癌腫瘤(具HER2低度表現)作為控制組,分別將搭-99m(I)-trastuzumab以尾靜脈注入於以上兩組小鼠中,於注射後6小時、24小時及48小時犧牲動物,取主要組織及器官連同腫瘤,稱重並測定其放射活度,計算出隨著時間分佈在 各器官組織每克所含注射劑量的百分比(%ID/g)。結果:我們發現錯-99m(I)-trastuzumab可專一特異性地累積於BT-474腫瘤,但對於MCF-7腫瘤則相對地累積甚低。注射後24小時腫瘤與正常肌肉組織比達最高,可作為最佳造影時間。結論:經本研究所得結果顯示錯-99m(I)-trastuzumab可進一步探討作為具HER2過度表現乳癌之造影劑。

英文摘要

Background: Tc-99m(1)-甘'astuzumab produced by direct labeling Tc-99m to trastuzumab using [Tc-99m (CO) ,(OH2),f as a precursor was assessed for its feasibility as an imaging agent for detec也19 HER2 expressing breast cancers by a biodis出bution study using athymic mice. Methods: BALB/c-nu mice were implanted with BT-474 breast cancer xenografts (wi也high HER2 expression). For a control condition,也e similar animals were implanted with MCF7 breast cancer xenografts (叫thlow HER2 expression). Tc-99m (1)-仕的tuzumabwas iniected in:甘avenously into each of the mice via the tail vein.τbe mice were sacrificed at 6 h, 24 h or 48 h pos叫ection and the major organs or tissues together with伽tumors were excised and counted for radioactivities. Biodis出bution was figured out企om the percentages of injected doses per gram (%ID/g) dis肘buted in the organs or tissues and the tumors along with the period of time after iniection. Results: Tc-99m (1)-trastuzumabwas found to specifically accumulate in the BT-474 tumor but relatively v前y low in the MCF-7 tumor. A suitable imaging at 24 h postinjection was proposed as observed from也e T!NT ratios at也is time; the tumor-to-muscle ratio for the Tc-99m (1)個stuzumabBT-474 tumor model up個ke reached its maximum and was significantly high compared to that姐MCF-7 tumor model. Conclusion:τbe biodis出bution result indicates that it is worthy to fur也er investigate the feasibility ofTc-99m (I)-trastuzumabfor imaging breast cancers with HER2 overexpression.

相關文獻